Tislelizumab vs Docetaxel in Previously Treated NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial
J Thorac Oncol 2022 Sep 29;[EPub Ahead of Print], C Zhou, D Huang, Y Fan, X Yu, Y Liu, Y Shu, Z Ma, Z Wang, Y Cheng, J Wang, S Hu, Z Liu, E Poddubskaya, U Disel, A Akopov, M Dvorkin, W Zheng, Y Ma, Y Wang, S Li, C Yu, G RivallandFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.